The evaluation of symptom burden in this study will assist in finding the best possible treatment with the least toxicity. 2 ELIGIBILITY ASSESSMENT AND ENROLLMENT 2.1 ELIGIBILITY CRITERIA The target population for this study is patients with newly diagnosed GBM with an un- methylated MGMT promoter and IDH wild type. NOTE: Enrollment to this protocol is closed.